SCHEMBL5403847

SCHEMBL5403847

NC(=O)c1ccc(C(F)(F)F)cc1C(F)(F)F.O=S(=O)(O)/C=C/c1ccc(Cl)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 3/20 0.51
FLT1 P17948 2/20 0.51
FLT4 P35916 2/20 0.51
CES2 O00748 2/20 0.45
AHR P35869 1/20 0.41
KDM1A O60341 1/20 0.39
LMNA P02545 2/20 0.37
XBP1 P17861 1/20 0.37
CASP1 P29466 1/20 0.36
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
ACLY P53396 1/20 0.36
TMPRSS4 Q9NRS4 1/20 0.36
CYP1A2 P05177 1/20 0.36
GPR52 Q9Y2T5 1/20 0.36
NPSR1 Q6W5P4 2/20 0.36
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5408837 0.89 FLT1 (0.44) KDRFLT1FLT4CES2CYP1A2
SCHEMBL27717773 0.89 MAOB (0.44) KDRFLT1FLT4LMNAXBP1
SCHEMBL5406602 0.89 MAOB (0.44) KDRFLT1FLT4LMNAXBP1
SCHEMBL5407610 0.88 CES2 (0.47) KDRFLT1FLT4CES2MAOB
SCHEMBL4619557 0.86 AHR (0.46) KDRFLT1FLT4AHRCASP1
SCHEMBL5418921 0.85 PTGES2 (0.47) CES2AHRMAOBCYP1A2
SCHEMBL5411196 0.85 GRIK1 (0.40) KDRFLT1FLT4MAOAMAOB
SCHEMBL27717857 0.85 GRIK1 (0.40) KDRFLT1FLT4MAOAMAOB
SCHEMBL27717780 0.85 PTGES2 (0.47) CES2AHRMAOBCYP1A2
SCHEMBL4253756 0.82 CES2 (0.43) KDRFLT1FLT4CES2GPR52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7208526-B2 For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US claimed
US-20060270874-A1 Styrylsulfonamides HOFFMANN-LA ROCHE INC. 2006-11-30 US claimed
US-7208526-B2 For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US disclosed
US-20060270874-A1 Styrylsulfonamides HOFFMANN-LA ROCHE INC. 2006-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270874-A1 Styrylsulfonamides STS, SULT1E1, BRCA1 KDR 4332/4885FLT1 4126/4885FLT4 4438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.